Table 1.
Detailed results of main network analysis.
| Treatment | RR (95% CI) for PASI 75 response |
SUCRA for PASI 75 response, % | RR (95% CI) for PASI 75 and above response |
SUCRA for PASI 75 and above response, % |
SMD (95% CI) for absolute PASI improvement |
SUCRA for absolute PASI improvement, % |
RR (95% CI) for withdrawal due to AEs |
SUCRA for withdrawal due to AEs, % |
RR (95%CI) for incidence of erythema |
SUCRA for incidence of erythema, % |
|---|---|---|---|---|---|---|---|---|---|---|
| PUVA | 1.06 (0.65, 1.71) | 26.9 | 0.94 (0.66, 1.34) | 23.5 | 1.41 (−2.13, 4.96) | 19.4 | Reference | 46.6 | Reference | 39.1 |
| UVB | 1.09 (0.63, 1.88) | 32.0 | 0.94 (0.64, 1.38) | 23.3 | 0.46 (−3.02, 3.95) | 23.3 | 0.95 (0.34, 2.68) | 49.3 | 0.89 (0.69, 1.16) | 65.8 |
| cPUVA | 1.47 (0.82, 2.64) | 86.0 | 1.15 (0.77, 1.73) | 81.1 | −0.76 (−4.10, 2.58) | 89.5 | 1.00 (0.29, 3.51) | 46.7 | 0.95 (0.59, 1.52) | 52.6 |
| cUVB | 1.38 (0.77, 2.47) | 79.0 | 1.13 (0.76, 1.68) | 78.4 | −0.89 (−3.93, 2.15) | 67.4 | 0.87 (0.23, 3.31) | 54.9 | 0.90 (0.61, 1.32) | 61.0 |
| cAB | Reference | 26.1 | Reference | 43.8 | Reference | 50.4 | 0.83 (0.02, 41.33) | 52.5 | 1.20 (0.44, 3.25) | 31.5 |